New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOvagen vs Leuprolide

Ovagen vs Leuprolide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Ovagen
Sexual Health & Libido
Leuprolide
Summary
Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
Half-Life
Short (minutes); sustained gene-regulatory effects
~3 hours (SC/IM), but depot formulations last 1–12 months
Admin Route
SubQ, Oral
SubQ, IM
Research
Typical Dose
10 mg per day
7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
Frequency
Daily for 10–30 days
Per depot schedule
Key Benefits
  • Hepatoprotective effects against toxic, viral, and metabolic liver damage
  • Promotes hepatocyte regeneration and liver tissue repair
  • May reduce liver fibrosis progression
  • Supports liver metabolic function and detoxification capacity
  • Anti-aging effects on hepatic tissue
  • Useful in NAFLD/MASH supportive protocols
  • Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
  • Medical: reduces testosterone in prostate cancer
  • Medical: suppresses estrogen in endometriosis and uterine fibroids
  • Medical: delays precocious puberty
  • Research: testosterone rebound effect after short course
  • Transgender care: hormone suppression in adolescents
  • Research: hormonal re-sensitization protocols
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No clinically significant hepatotoxicity reported
  • Hot flashes (with testosterone suppression)
  • Decreased libido and erectile dysfunction
  • Initial testosterone flare (first 1–2 weeks)
  • Bone density loss with long-term use
  • +3 more
Stacks With